These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 17673045)
41. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Tang JM; He QY; Guo RX; Chang XJ Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768 [TBL] [Abstract][Full Text] [Related]
42. [Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue]. Tang L; Wang M; Ma J Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):687-90. PubMed ID: 12487927 [TBL] [Abstract][Full Text] [Related]
43. Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Jung YW; Kim YT; Kim SW; Kim S; Kim JH; Cho NH; Kim JW Reprod Sci; 2009 Nov; 16(11):1103-11. PubMed ID: 19692629 [TBL] [Abstract][Full Text] [Related]
44. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716 [TBL] [Abstract][Full Text] [Related]
45. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. Min H; Wei-hong Z J Obstet Gynaecol Res; 2009 Oct; 35(5):918-25. PubMed ID: 20149042 [TBL] [Abstract][Full Text] [Related]
46. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562 [TBL] [Abstract][Full Text] [Related]
47. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877 [TBL] [Abstract][Full Text] [Related]
48. [Correlation of genetic instability of nm23H1 gene to clinicopathologic features of epithelial ovarian carcinoma]. Yang YQ; Li JC Ai Zheng; 2006 Jun; 25(6):713-7. PubMed ID: 16764766 [TBL] [Abstract][Full Text] [Related]
49. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113 [TBL] [Abstract][Full Text] [Related]
50. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Osman I; Dai J; Mikhail M; Navarro D; Taneja SS; Lee P; Christos P; Shen R; Nanus DM Cancer; 2006 Dec; 107(11):2628-36. PubMed ID: 17083125 [TBL] [Abstract][Full Text] [Related]
51. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Schindl M; Schoppmann SF; Ströbel T; Heinzl H; Leisser C; Horvat R; Birner P Clin Cancer Res; 2003 Feb; 9(2):779-85. PubMed ID: 12576450 [TBL] [Abstract][Full Text] [Related]
52. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M Anticancer Res; 2002; 22(6A):3191-6. PubMed ID: 12530064 [TBL] [Abstract][Full Text] [Related]
53. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors]. Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316 [TBL] [Abstract][Full Text] [Related]
54. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Badiglian Filho L; Oshima CT; De Oliveira Lima F; De Oliveira Costa H; De Sousa Damião R; Gomes TS; Gonçalves WJ Oncol Rep; 2009 Feb; 21(2):313-20. PubMed ID: 19148501 [TBL] [Abstract][Full Text] [Related]
55. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120 [TBL] [Abstract][Full Text] [Related]
56. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Jang KS; Song YS; Jang SH; Min KW; Na W; Jang SM; Jun YJ; Lee KH; Choi D; Paik SS Histopathology; 2010 Jan; 56(2):229-39. PubMed ID: 20102402 [TBL] [Abstract][Full Text] [Related]
57. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer. Magkou C; Mylona E; Theohari I; Giannopoulou I; Papanikolaou E; Markaki S; Nakopoulou L In Vivo; 2007; 21(6):967-72. PubMed ID: 18210742 [TBL] [Abstract][Full Text] [Related]
58. [Clinical significance of matrix metalloproteinase-2 expression in patients with epithelial ovarian tumor]. Wu X; Li H; Song J Zhonghua Fu Chan Ke Za Zhi; 2001 Oct; 36(10):621-4. PubMed ID: 16134528 [TBL] [Abstract][Full Text] [Related]
59. Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Klasa-Mazurkiewicz D; Narkiewicz J; Milczek T; Lipińska B; Emerich J Gynecol Oncol; 2009 Apr; 113(1):91-8. PubMed ID: 19193429 [TBL] [Abstract][Full Text] [Related]